Cardiac exams represent only about five percent of all CT procedures, but cardiac CT continues to generate the most interest at manufacturers’ exhibits as seen at the 2006 RSNA Annual Scientific Meeting. The fascination with Cardiovascular Computed Tomography (CVCT) remains high even though full reimbursement is not expected to occur until 2009, according to industry observers at RSNA.

The modern world of medicine has been revolutionized by the inception of minimally invasive interventional techniques. Vascular closure device (VCD) technology is a relatively new technology that has drafted new vistas to drive interventional surgery a step further.
Physicians' awareness and willingness to use new technology plays a vital role in the success of a device. Advances in the field of catheter-based cardiovascular treatments address the need for optimum vascular access hemostasis.

March 22 2007 — ZOLL Medical Corp announced today it received FDA clearance to market and sell the ZOLL M Series with Real CPR Help technology. The device enables rescuers to instantly see and hear how well they are performing the rate and depth of CPR chest compressions.

The M Series is the Company’s best-selling product to date. The approval extends Real CPR Help to ZOLL’s complete defibrillator product line.

For more information visit www.zoll.com

March 22, 2007 — Edwards Lifesciences Corp. says it has received conditional FDA approval to initiate a pivotal clinical trial of the SAPIEN transcatheter aortic heart valve technology. The PARTNER (Placement of AoRTic traNscathetER valves) trial will evaluate the SAPIEN valve in patients who are considered high risk for conventional open-heart valve surgery.

March 22, 2007 — Evalve, Inc., a privately held medical device company, has announced the FDA has approved a registry of up to 70 patients who are at high risk of mortality from surgical treatment for mitral regurgitation (MR) as part of its ongoing pivotal EVEREST Study (Endovascular Valve Edge-to-Edge REpair STudy).

March 22, 2007 — MedicalCV Inc. has announced it has received FDA clearance for its SOLAR Surgical Ablation System for the ablation of soft tissue. The company developed the SOLAR System to enable automated, computer-controlled ablation in surgical procedures utilizing laser energy.

MedicalCV Inc. is a medical device company that develops, manufactures and sells surgical ablation systems that utilize a laser energy technology platform to create precise lesions, or scars, on soft and cardiac tissues. The Company's core technologies are the SOLAR and ATRILAZE

March 22, 2007 — Pfizer says the FDA has approved the company’s Lipitor (atorvastatin calcium) Tablets to reduce the risk of nonfatal heart attacks, fatal and non-fatal strokes, certain types of heart surgery, hospitalization for heart failure, and chest pain in patients with heart disease — making Lipitor the first cholesterol-lowering medication to receive FDA approval for the reduction of the risk of hospitalization for heart failure.

March 22, 2007 — St. Jude Medical Inc. says it has received FDA approval of a new cardiac rhythm management device designed to help physicians manage heart failure (HF) patients, including patients who have or may develop atrial fibrillation (AF).

March 22, 2007 — McKesson has announced it has expanded its distribution agreement with Toshiba America Medical
Systems, Inc., to include cardiovascular medical solutions. Nine months ago the two companies had announced their initial radiology imaging partnership, which has been a success, they say.

The Human Patient Simulator (HPS) – a computer-model-driven, full-sized mannequin – delivers experience in true-to-life scenarios that swiftly change to meet instructors’ goals. The sophisticated and versatile HPS blinks, speaks and breathes, has a heartbeat and a pulse, and accurately mirrors human responses to such procedures as CPR, intravenous medication, intubation, ventilation and catheterization.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now